Abstract
A clinical trial of uncomplicated skin and skin structure infections (39 locations in 19 states) observed that community-associated or community-onset methicillin-resistant Staphylococcus aureus (CO-MRSA) represented 23% of all pathogens at baseline culture and 53% of 190 S. aureus isolates. CO-MRSA strains typically were Panton-Valentine leukocidin (PVL) positive (95%), contained staphylococcal cassette chromosome mec type IVa (99%), were USA300 or USA400 clones (92%), and exhibited minimal coresistances (macrolides and/or fluoroquinolones). Clinical results remained identical (89% cures) regardless of the antimicrobial used or CO-MRSA molecular patterns, PVL production, or antimicrobial susceptibility profiles.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Bacterial Proteins / genetics
-
Bacterial Toxins / metabolism
-
Clinical Trials as Topic
-
Community-Acquired Infections / microbiology
-
Electrophoresis, Gel, Pulsed-Field
-
Exotoxins / metabolism
-
Humans
-
Leukocidins / metabolism
-
Methicillin Resistance / genetics
-
Multicenter Studies as Topic
-
Penicillin-Binding Proteins
-
Reverse Transcriptase Polymerase Chain Reaction
-
Skin Diseases, Infectious / microbiology*
-
Staphylococcal Infections / epidemiology
-
Staphylococcal Infections / microbiology
-
Staphylococcus aureus / drug effects
-
Staphylococcus aureus / genetics*
Substances
-
Bacterial Proteins
-
Bacterial Toxins
-
Exotoxins
-
Leukocidins
-
Panton-Valentine leukocidin
-
Penicillin-Binding Proteins
-
mecA protein, Staphylococcus aureus